OUR EVENTS

UPCOMING ANABIOS EVENTS

AnaBios offers early human insights into the drug development process and is redefining ‘First-in-Human’ studies. 

JUN

27

WEBINAR | Human Ventricular Action Potential & E14 Waivers for Novel Drugs

  • Online

Details:

VP of Research & Development Najah Abi-Gerges, Ph.D. and Derek Leishman, Ph.D., VP of Translational and Qualitative Toxicology at Eli Lilly, will discuss a ventricular action potential assay that can contribute to E14 waiver request data sets.

Register

NEED ASSISTANCE?

TALK WITH OUR EXPERTS

Learn More